Open access
Open access
Powered by Google Translator Translator

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

9 Aug, 2021 | 00:06h | UTC

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial – The Lancet

Invited commentary: Optimising SARS-CoV-2 vaccination schedules – The Lancet

Related: Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (several articles on the subject)

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.